Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03019029 · ClinicalTrials.gov registry record · Phase 1
Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT03019029: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT03019029 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03019029, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The primary aim of this study will be to examine the diagnostic utility of 18-F Florbetapir PET/MR (Positron Emission Tomography/Magnetic Resonance) in imaging patients with pathologically-confirmed systemic amyloidosis involving the peripheral nerves and compare these results to non-amyloid diseased controls.
Interventions
- OTHER 18-F Florbetapir PET/MR scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2017-03-13 |
| Est. Completion | 2022-03-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03019029
The ClinicalTrials.gov registry entry for NCT03019029 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 18-F Florbetapir PET/MR scan is the first listed.
NCT03019029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03019029 about?
NCT03019029 is a clinical study titled "Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis". The primary aim of this study will be to examine the diagnostic utility of 18-F Florbetapir PET/MR (Positron Emission Tomography/Magnetic Resonance) in imaging patients with pathologically-confirmed systemic amyloidosis involving the peripheral nerves and compare these results to non-amyloid disease...
What is the current status of trial NCT03019029?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2017-03-13. Estimated completion is 2022-03-24.
What interventions are being tested in trial NCT03019029?
The interventions under investigation include: 18-F Florbetapir PET/MR scan (OTHER).
Who is sponsoring clinical trial NCT03019029?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.